Leaving Merck to Build a Biotech From Scratch | Örn Almarsson (2/4)

At Merck, a three-month visa detour exposed Örn to another laboratory and reinforced the value of adaptability. He then describes leaving a secure role for Transform Pharmaceuticals, building a small team and collaborative culture, developing new formulation technologies, and helping create the patents and assets that led to a Johnson & Johnson acquisition.